Valipour Mehdi, Zakeri Khatir Zahra, Abdollahi Elaheh, Ayati Adileh
Razi Drug Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari 6964114483, Iran.
ACS Pharmacol Transl Sci. 2023 Dec 28;7(1):48-71. doi: 10.1021/acsptsci.3c00292. eCollection 2024 Jan 12.
Berberine is a well-known phytochemical with significant antiviral activity against a wide range of viruses. Due to having a unique backbone consisting of four interconnected rings, it can be used as a platform for the design and development of novel semisynthetic antiviral agents. The question here is whether novel broad-spectrum antiviral drugs with enhanced activity and toxicity potential can be obtained by attempting to modify the structure of this privileged lead compound. The present study aims to review the results of recent studies in which berberine and its close analogues (protoberberine alkaloids) have been used as starting materials for the production of new semisynthetic antiviral structures. For this purpose, relevant studies published in high-quality journals indexed in databases such as Scopus, Web of Science, PubMed, etc. in the time frame of 2017 to 2023 were collected. Our selection criterion in the current review focuses on the studies in which protoberberines were used as starting materials for the production of semisynthetic agents with antiviral activity during the indicated time period. Correspondingly, studies were identified in which semisynthetic derivatives with significant inhibitory activity against a wide range of viruses including human immunodeficiency virus (HIV), enterovirus 71 (EV71), zika virus (ZIKV), influenza A/B, cytomegalovirus (CMV), respiratory syncytial virus (RSV), and coxsackieviruses were designed and synthesized. Our conclusion is that, despite the introduction of diverse semisynthetic derivatives of berberine with improved activity profiles compared to the parent natural leads, sufficient derivatization has not been done yet and more studies are needed.
黄连素是一种著名的植物化学物质,对多种病毒具有显著的抗病毒活性。由于其具有由四个相互连接的环组成的独特骨架,它可作为设计和开发新型半合成抗病毒药物的平台。这里的问题是,通过尝试修饰这种具有优势的先导化合物的结构,是否能够获得具有增强活性和潜在毒性的新型广谱抗病毒药物。本研究旨在综述近期的研究结果,其中黄连素及其类似物(原小檗碱生物碱)已被用作生产新的半合成抗病毒结构的起始原料。为此,收集了2017年至2023年期间发表在Scopus、Web of Science、PubMed等数据库索引的高质量期刊上的相关研究。我们在本次综述中的选择标准侧重于在指定时间段内将原小檗碱用作生产具有抗病毒活性的半合成药物的起始原料的研究。相应地,确定了一些研究,其中设计并合成了对包括人类免疫缺陷病毒(HIV)、肠道病毒71型(EV71)、寨卡病毒(ZIKV)、甲型/乙型流感病毒、巨细胞病毒(CMV)、呼吸道合胞病毒(RSV)和柯萨奇病毒在内的多种病毒具有显著抑制活性的半合成衍生物。我们的结论是,尽管引入了与母体天然先导化合物相比活性谱有所改善的多种黄连素半合成衍生物,但尚未进行充分的衍生化,仍需要更多的研究。